Compass Therapeutics (CMPX) Cash from Operations (2018 - 2026)

Compass Therapeutics has disclosed Cash from Operations across 9 years of filings, most recently posting 17269000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 17269000.0, down 30.75% year-over-year; the trailing twelve-month figure through Mar 2026 was 53204000.0 (down 20.44% YoY), and the FY2025 annual result was 49143000.0, down 9.56% from the prior year.
• Cash from Operations came in at 17269000.0 for Q1 2026 at Compass Therapeutics, down from 13254000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 4600000.0 in Q2 2022 to a low of 17269000.0 in Q1 2026.
• The 5-year median for Cash from Operations is 10942000.0 (2022), against an average of 10941764.71.
• Across the five-year window, Cash from Operations slumped 216.52% in 2022 and soared 45.88% in 2023, its largest moves.
• Compass Therapeutics' Cash from Operations stood at 10641000.0 in 2022, then slipped by 16.1% to 12354000.0 in 2023, then increased by 25.84% to 9162000.0 in 2024, then slumped by 44.66% to 13254000.0 in 2025, then tumbled by 30.29% to 17269000.0 in 2026.
• The last three Cash from Operations figures came in at 17269000.0 (Q1 2026), 13254000.0 (Q4 2025), and 10849000.0 (Q3 2025), per Business Quant data.